1. Home
  2. MLEC vs BCAB Comparison

MLEC vs BCAB Comparison

Compare MLEC & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moolec Science SA

MLEC

Moolec Science SA

HOLD

Current Price

$8.30

Market Cap

5.6M

Sector

Finance

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$3.56

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLEC
BCAB
Founded
2008
2007
Country
Cayman Islands
United States
Employees
72
N/A
Industry
Blank Checks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
6.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MLEC
BCAB
Price
$8.30
$3.56
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
19.9K
35.1K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.86
EPS
N/A
N/A
Revenue
N/A
$300,000.00
Revenue This Year
$20.42
N/A
Revenue Next Year
$30.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.12
52 Week High
$23.22
$6.52

Technical Indicators

Market Signals
Indicator
MLEC
BCAB
Relative Strength Index (RSI) 54.89 49.11
Support Level $8.09 $3.19
Resistance Level $9.23 $5.18
Average True Range (ATR) 0.89 0.33
MACD 0.11 0.01
Stochastic Oscillator 62.09 61.49

Price Performance

Historical Comparison
MLEC
BCAB

About MLEC Moolec Science SA

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: